Impel Neuropharma Inc., of Seattle, said it completed a series D financing raising $67.5 million. The investment was co-led by KKR and Norwest Venture Partners, with participation from existing investors Vivo Capital, 5AM Ventures and Venbio Partners. The funding will enable the company to accelerate its existing clinical development portfolio in CNS disorders.